Transcription
CSE: CURE OTCQB: BICTFFRONT RUNNER INCAR-T CELL THERAPYFOR CANCER PATIENTSInvestor Presentation, June 2021BIOCURE TECHNOLOGY INC. (CSE:CURE OTCQB:BICTF)1INVESTOR BRIEFING – JUNE 2021
BIOCURE PHARMA INTROUsing genetic engineering to deliver new treatments for aggressive cancersBiocure Pharmais a leadingbiotech companydeveloping itsCAR-T cell therapyfor leukemia, lung,breast andpancreatic cancerBIOCURE TECHNOLOGY INC. (CSE:CURE OTCQB:BICTF)2Biocure,headquartered inKorea, has jointventure partners inAsia and Europewith planned clinicaltrials commencingin 2021INVESTOR BRIEFING – JUNE 2021
HISTORY TO DATESubstantial investment and business progression made2021Phase I clinicaltrial ished in a50/50 joint venturewith MacauleyGehler fromSingapore2016BiocurePharm-Swissestablished in ajoint venture withSibitec fromSwitzerland2017Announced CAR-Tcell Therapy(BCP401) ClinicalTrial Plan2017Listed on theCanadian StockExchange (CSE)Pre-2017BIOCURE TECHNOLOGY INC. (CSE:CURE OTCQB:BICTF)2018Completedpre-clinical trial ofCAR-T cell TherapyBCP401 –first in Korea2018Dual listing onUS OTC market2017-201832021Dual listing onFrankfurt Exchangeplanned2020MOU withS&B Biopharma,Bulgaria for buildingCAR-T productionplant in Europe2019Contracted CROfor clinical trial ofBCP4012020Submissionof BCP401IND Plan2020MOU with Symbasisin Germany for EUclinical trials2019-2021INVESTOR BRIEFING – JUNE 2021
BUSINESS HIGHLIGHTSPositioned to capture value by commercializing BCP401Front runner to commercialize its BCP401 CAR-T cell therapy in KoreaTwo terminally ill patients showed Complete Remission after 1 month of BCP401 CAR-T cell therapyHigh efficacy and safety data for BCP401 in place in readiness for Phase I clinical trialProvides Asia & Europe a potentially more cost efficient CAR-T cell therapy where US equivalentis 475,000 per doseDerisked clinical pathway using CD19 antigen, a proven approachPipeline of opportunities using the approach in a highly active market seeking solutionsBIOCURE TECHNOLOGY INC. (CSE:CURE OTCQB:BICTF)4INVESTOR BRIEFING – JUNE 2021
CAR-T CELL THERAPYBIOCURE TECHNOLOGY INC. (CSE:CURE OTCQB:BICTF)5CSE: CURE OTCQB: BICTFINVESTOR BRIEFING – JUNE 2021
CAR-T CELL THERAPY: CANCER BREAKTHROUGHComplete remission was achieved in 90% of patients from a single injectionAcute lymphoblasticleukemia (ALL) is difficult totreat despite the availabilityof aggressive therapies2012-14UPenn: A total of 30 children andadults received CAR-T cell therapytargeting the CD19 antigenComplete remission wasachieved in 27 patients (90%)2017-18U.S. FDA approved, Kymriah ,an anti-CD19 antigen CAR-Tcell therapy for ALL(US 475k per dose)The first patient (a 7-year old) enrolled inclinical trial of CAR-T cell Immunotherapycompletely recovered with a singleadministration and is living cancer free morethan 5 years after the treatment- Emily WhiteheadBIOCURE TECHNOLOGY INC. (CSE:CURE OTCQB:BICTF)6INVESTOR BRIEFING – JUNE 2021
CAR-T CELL THERAPY MECHANISMUses a patient’s own immune system to fight certain types of cancerT-cells arecollected fromthe patientT-cells aregeneticallymodified withChimeric AntigenReceptor to createCAR-T cellsBIOCURE TECHNOLOGY INC. (CSE:CURE OTCQB:BICTF)CAR-T cellsare multiplied7CAR-T cellsare infusedinto the bodyCAR-T cells tracksdown specificantigen on thecancer cell andkills patientcancer cellsINVESTOR BRIEFING – JUNE 2021
MARKET SITUATIONBiocure is targeting market entry with a cost-effective icing (US )Kymriah (tisagenlecleucel)CD19NovartisFDA approvedALL 475,000, per 1 doseYescarta (axicabtagene ciloleucel)CD19Gilead / KITEFDA approvedNon-Hodgkin lymphoma 373,000 per 1 doseJCAR017 (lisocabtagene marealeucel)CD19BMS / JunoSubmissionLeukemia, lymphoma, NHLBB2121 (idecabtagene ciclucel)BMCACelgenePhase IIMultiple myelomaAUTO-1CD19AutolusPhase I/IILeukemia, lymphomaJCAR104CD19JunoPhase INHLUCART19CD19Cellectis / Servier / AllogenePhase ILeukemia, lymphomaBCP401CD19Biocure PharmSubmission to INDALLBIOCURE TECHNOLOGY INC. (CSE:CURE OTCQB:BICTF) Front runner of commercializing CAR-T cell therapy in Korea Targeting CD19, a proven approach to ALL Potential to provide a more cost efficient priced ALL-targetedproduct to Asia and Europe8INVESTOR BRIEFING – JUNE 2021
BIOCURE PHARMBIOCURE TECHNOLOGY INC. (CSE:CURE OTCQB:BICTF)CSE: CURE OTCQB: BICTF9INVESTOR BRIEFING – JUNE 2021
BIOCURE PHARM BUSINESS PLANStrategic growth plan2. JV to progressinternationalopportunities1. Progress BCP401for ALL in KoreaMOU in Bulgaria formanufacturing,progress BCP402 forCLL in Germany andcommence BCP401internationally inMalaysiaComplete Phase I & IIclinical trials, obtainproduct approval andlaunch to market inKorea by end 20223. Uplisting to amajor US exchangeSignificant technologybased IPO for 2023 asCAR-T trials enter finalstagesBiocure Pharm proposes to supply BCP401 CAR-T cell treatment ata price of 60 70% of existing FDA approved productsBIOCURE TECHNOLOGY INC. (CSE:CURE OTCQB:BICTF)10INVESTOR BRIEFING – JUNE 2021
OUR PIPELINENumerous value inflection points for coming 24 monthsProgramIndication (Target) Approach & StatusDiscovery Pre-clinicalPhase IPhase II CAR-T therapy targeting CD19 antigenBCP401Leukemia Preclinical efficacy / toxicity test completed, together withestablishment of manufacturing and other processes to submitits IND application in December 2020 Phase I of 9-12 patients to evaluate the safety and tolerability ofBCP401, followed by Phase II of 30 patientsBCP402BCP403Lung Cancer,Breast Cancer andPancreatic CancerSolid tumor20212022 ROR1 is an antigen specific to CLL cancer cell and expression innormal cell is very low (making it suitable for CLL diagnostic orCAR-T treatment) Established JV ‘Oncocart’ with Koln University Hospital Clinical inGermany to progress CAR-T therapy targeting ROR1 hase II in2022Out-licenseto bigpharmaafterPhase II Therapy to regulate expression of suppressor receptor of tumorcells with potential to develop relevant antibodies and receptorsBIOCURE TECHNOLOGY INC. (CSE:CURE OTCQB:BICTF)11INVESTOR BRIEFING – JUNE 2021
BCP401 VALUE PROPOSITIONAttractive proposition clinically and operationallyKey FeaturesBenefitEstablished safety profilePre-clinical data shown to have a good efficacy and toxicity test profileIn-built ‘targeting’ of BCP401 for CD19Delivered via IV infusion with CAR-T cell therapy targeting CD19 antigen on cancer cellsDemonstrated in patientsResearcher clinical trial for therapeutic purposes in China and conducted with patientsenrolled in between June 2017 through June 2018 demonstrated complete remission in53 of 56 patients (94%)Effective at low doseCAR-T shown to have good response with a single administrationCompetitive to existing FDA approvedCAR-T therapiesIn China trial, BCP shown to have an overall survival rate superior to currentFDA-approved CAR-T therapiesCost-effective to manufactureManufacturing locations in Bulgaria and Malaysia offering substantial reduction in costof manufacturingLocalised version to win outside USOffering BCP401 at a price of 60-70% of existing FDA approved products provides asignificant reduction of healthcare costs in Asia and EuropeBIOCURE TECHNOLOGY INC. (CSE:CURE OTCQB:BICTF)12INVESTOR BRIEFING – JUNE 2021
INVESTIGATOR CLINICAL TRIAL OF BCP401Conducted at Beijing University Hospital in China using CAR-T cell therapyCAR-T cell therapy for trial provided by Pharos Vaccine, a collaborativeresearch and development company of BiocurePharm56 subjects with relapse/refractory ALL (1 25 age) patients enrolled inbetween June 2017 through June 2018Overall Response Rate to BCP40198.2%55/56CAR-T program had good response with a single dose.Adverse events were immune responses related to CAR-T cell proliferationand cytokines (similar results with Kymriah )It was possible to control adverse events with IL-6 inhibitor andcorticosteroidComplete Remission after BCP40194.6%53/56Overall response rate was 55/56 (98.21%) and complete remission in53 of 56 (94.64%). All patients were alive at 3 monthsBIOCURE TECHNOLOGY INC. (CSE:CURE OTCQB:BICTF)13INVESTOR BRIEFING – JUNE 2021
MARKET POTENTIAL OF BCP401Substantial revenue potential once in marketNumber of patients with lymphatic leukemia in KoreaLeukemia is the most prevalent diseasefor children under 14 years6,630 1.99BBiocure is targeting a one-timetreatment fee of approx. 340 millionwon (approx. 300,000 USD)6,350 1.91B6,062 1.82B5,863This is a substantial market in Koreaalone (approx. US 2 billion) withexpansion potential through Asiaand Europe 1.76B2016201720182019*US market value assumes US 300,000 per patientBIOCURE TECHNOLOGY INC. (CSE:CURE OTCQB:BICTF)14INVESTOR BRIEFING – JUNE 2021
BOARD OF DIRECTORSExperienced leadership teamDr. Sang Mok LeeCEO & President, DirectorMr. Konstantin LichtenwaldCFO, DirectorMr Collin (Sang Goo) KimDirectorMr. Berkan UnalDirectorDr. Danny JohDirector President and CEO of BiocureTechnology since theinception in 2005 Over 15 years’ finance andaccounting experience,including corporatecompliance, accounting andfinancial management andIPO, RTO services Holds a bachelor degree ofbusiness administration fromKorea University, Seoul, Korea. Over 10 years’ experience inthe biopharmaceuticalindustry in Germany andSwitzerland and connectionsto global leaders in thebiopharmaceutical sector 20 years’ biopharma productdevelopment and crossfunctional programmanagement experienceswith Chiron, Genentech,Biomarin, Sangamo and otherbiotech companies Holds a PhD in microbiologyfrom Busan National Universityin Korea and is currently anadjunct professor inmicrobiology at ChungnamNational University A committee member for thehi-tech medical complex cityin Daejon, Korea and acommittee member of KOFST(the Korean Federation ofScience and TechnologySocieties) Extensive knowledge andknow-how for companies inNorth America and Germanspeaking parts of Europe A Chartered ProfessionalAccountant (CPA, CGA) andChartered CertifiedAccountant (ACCA), where heis a member of CharteredProfessional Accountants ofB.C. and Canada as well as amember of the Association ofChartered CertifiedAccountants of UnitedKingdomBIOCURE TECHNOLOGY INC. (CSE:CURE OTCQB:BICTF) Moved to Vancouver, Canadain 2006 after working forHanwha Corp., one of Koreanbusiness conglomerates for 16years, where he was dedicatedto International tradingbusiness Vice President for ColumbiaCapital since 2008 and adirector of ArcPacificResources Corp., a publicCanadian junior explorationcompany, since 2015 Communicates betweenKorean management andCanadian management crossthe border with his vastknowledge and workexperience15 Currently, acts as businessdevelopment director forbiologics, gene and celltherapy of GenScript Biotech,a global leading biotechcompany, and has beeninvolved in the processes thatprovide end-to-end solutionsfrom discovery tocommercialization Studied bioprocessengineering and medicalbiotechnology at BerlinTechnical University ofApplied Sciences, HamburgUniversity of Technology andImperial College London Experience spans from earlyto late stage productdevelopment in variousplatforms, including biologics,small molecules, and genetherapy across manytherapeutic areas, includingcancer and rare geneticdisorders PhD in Biochemistry at TexasA&M university and an MBA atRice UniversityINVESTOR BRIEFING – JUNE 2021
CAPITAL STRUCTURECapital structureNo. of shares% heldBoard and management30.0m30.0%Other shareholders69.9m70.0%Total shares on issue99.9m100.0%Options (exercise price CAD0.30)6.32mWarrants (exercise price CAD0.21)1.81mShare priceCAD0.175Market capitalisationBIOCURE TECHNOLOGY INC. (CSE:CURE OTCQB:BICTF)CAD17.48m16INVESTOR BRIEFING – JUNE 2021
NOTICES & DISCLAIMERImportant Notice & Disclaimer“Forward Looking Statements” DisclaimerThis presentation has been prepared by the management of the ‘Company’ inconnection with meetings with private and institutional investors, and not asspecific advice to any particular party or person. The information is based onpublicly available information, internally developed data and other sources.Where any opinion is expressed in this presentation, it is based on theassumptions and limitations mentioned herein and is an expression of presentopinion only. No warranties or representations can be made as to the origin,validity, accuracy, completeness, currency or reliability of the information. TheCompany disclaims and excludes all liability (to the extent permitted by law) forlosses, claims, damages, demands, costs and expenses of whatever naturearising in any way out of or in connection with the information, its accuracy,completeness or by reason of reliance by any person on any of it.The documents provided contain statements related to our future business andfinancial performance and future events or developments involving theCompany that may constitute forward-looking statements. These statements maybe identified by words such as "expects," "looks forward to," "anticipates,""intends," "plans," "believes," "seeks," "estimates," "will," "project" or words ofsimilar meaning. We may also make forward-looking statements in other reports,in presentations, in material delivered to stockholders and in press releases. Inaddition, Company representatives may from time to time make oral forwardlooking statements. Such statements are based on the current expectations andcertain assumptions of the Company’s management, and are, therefore, subjectto certain risks and uncertainties. A variety of factors, many of which are beyondthe Company’s control, affect the Company’s operations, performance, businessstrategy and results and could cause the actual results, performance orachievements of the Company to be materially different from any future results,performance or achievements that may be expressed or implied by suchforward-looking statements or anticipated on the basis of historical trends. Dueto rounding, numbers presented throughout this and other documents may notadd up precisely to the totals provided and percentages may not precisely reflectthe absolute figures. The documents provided in this presentation includesupplemental financial measures that are or may be non-GAAP financialmeasures.BIOCURE TECHNOLOGY INC. (CSE:CURE OTCQB:BICTF)17INVESTOR BRIEFING – JUNE 2021
CSE: CURE OTCQB: BICTFWebsite:Email ss:300-1055 West Hastings StreetVancouver, BC V6E 2E9Canada 1 604-609-7146PhoneInvestor Relations (North America)Purple Crown Communications Corp.Ms Julie HajdukEmail: Julie@purplecrown.caBIOCURE TECHNOLOGY INC. (CSE:CURE OTCQB:BICTF)18INVESTOR BRIEFING – JUNE 2021
Front runner to commercialize its BCP401 CAR-T cell therapy in Korea. Two terminally ill patients showed Complete Remission after 1 month of BCP401 CAR-T cell therapy . High efficacy and safety data for BCP401 in place in readiness for Phase I clinical trial. Provides Asia & Europe a potentially more cost efficient CAR-T cell therapy where US equivalent is 475,000 per dose. Derisked clinical .
